BDBM294357 US9586950, 24::methyl 4-cyano-2-({(3R,6R)-1-[(2- fluoro-6-pyrimidin-2- ylphenyl)carbonyl]-6- methylpiperidin-3-yl}oxy)pyridine- 3-carboxylate

SMILES COC(=O)c1c(O[C@@H]2CC[C@@H](C)N(C2)C(=O)c2c(F)cccc2-c2ncccn2)nccc1C#N

InChI Key InChIKey=OHYMYLVQQRBIMN-NVXWUHKLSA-N

Data  2 KI  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 294357   

TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294357(US9586950, 24 | methyl 4-cyano-2-({(3R,6R)-1-[(2- ...)
Affinity DataKi:  0.420nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294357(US9586950, 24 | methyl 4-cyano-2-({(3R,6R)-1-[(2- ...)
Affinity DataKi:  48nMAssay Description:Described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294357(US9586950, 24 | methyl 4-cyano-2-({(3R,6R)-1-[(2- ...)
Affinity DataIC50:  32.8nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM294357(US9586950, 24 | methyl 4-cyano-2-({(3R,6R)-1-[(2- ...)
Affinity DataIC50:  380nMAssay Description:. In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent